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Abstract
Background: Hodgkin's lymphoma (HL) survivors who undergo radiotherapy experience increased risks of
second cancers (SC) and cardiac sequelae. To reduce such risks, extended-field radiotherapy (RT) for HL has
largely been replaced by involved field radiotherapy (IFRT). While it has generally been assumed that IFRT will
reduce SC risks, there are few data that quantify the reduction in dose to normal tissues associated with modern
RT practice for patients with mediastinal HL, and no estimates of the expected reduction in SC risk.
Methods: Organ-specific dose-volume histograms (DVH) were generated for 41 patients receiving 35 Gy mantle
RT, 35 Gy IFRT, or 20 Gy IFRT, and integrated organ mean doses were compared for the three protocols. Organ-
specific SC risk estimates were estimated using a dosimetric risk-modeling approach, analyzing DVH data with
quantitative, mechanistic models of radiation-induced cancer.
Results: Dose reductions resulted in corresponding reductions in predicted excess relative risks (ERR) for SC
induction. Moving from 35 Gy mantle RT to 35 Gy IFRT reduces predicted ERR for female breast and lung cancer
by approximately 65%, and for male lung cancer by approximately 35%; moving from 35 Gy IFRT to 20 Gy IFRT
reduces predicted ERRs approximately 40% more. The median reduction in integral dose to the whole heart with
the transition to 35 Gy IFRT was 35%, with a smaller (2%) reduction in dose to proximal coronary arteries. There
was no significant reduction in thyroid dose.
Conclusion: The significant decreases estimated for radiation-induced SC risks associated with modern IFRT
provide strong support for the use of IFRT to reduce the late effects of treatment. The approach employed here
can provide new insight into the risks associated with contemporary IFRT for HL, and may facilitate the counseling
of patients regarding the risks associated with this treatment.
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It has long been established that Hodgkin's lymphoma
(HL) survivors experience increased risks of secondary
cancer (SC), in particular breast and lung cancer, and car-
diac disease attributable in part to radiotherapy (RT) [1-
6]. Most published estimates of SC risks after RT in HL sur-
vivors [5-8] are based on results from patients treated with
extended-field RT, (that is, mantle, extended mantle or
subtotal nodal RT fields that included both grossly
enlarged lymph nodes as well as surrounding lymph
nodes), which was widely used prior to the mid 1990s [9].
Since that time, in large part to reduce the risks of SC and
cardiac toxicity, extended field radiotherapy for HL has
generally been superceded by involved field radiation
therapy (IFRT) delivered following chemotherapy [10].
Furthermore, reduced-dose IFRT (20 Gy) appears to pro-
duce comparable early disease control for selected favora-
ble and intermediate risk patients, suggesting that this
may become the standard adjuvant RT dose [11,12].
Since the advent of IFRT is relatively recent, there are few
data to support or refute the assumption that reduced RT
volumes will lead to a reduction in SC. A meta-analysis of
10 randomized trials found a significant reduction in the
risk of breast cancer following IFRT compared to EFRT,
but no significant reduction in the overall risk of all forms
of SC combined [13]. Among 8 trials primarily involving
early stage patients, there was a non-significant increase in
SC rate among treatments that included EFRT (Odds
Ratio, OR = 1.20, 95%CI = 0.88–1.62) [13]. Similarly, no
difference in SC rate was found among 603 patients
treated in British National Lymphoma Investigation
(BNLI) Study [14].
A major limitation of standard observational studies of SC
is the long latency required to observe the outcome and
the resulting difficulty predicting the potential benefit
associated with recent or potential future changes in prac-
tice (e.g. dose reduction to 20 Gy). An alternative, compli-
mentary approach to these epidemiologic estimates of SC
risk involves biologically-based modeling of SC risk. Until
recently however, it was not practical to estimate SC risks
after HL radiotherapy, because there was considerable
uncertainty about the appropriate dose-responses for radi-
ation-induced cancer at high radiation doses [15]. Older
models of radiation carcinogenicity suggested that with
increasing radiation doses above approximately 5 Gy, cel-
lular killing offsets the induction of pre-malignancy, and
the risk of developing radiation-induced SC declines
[16,17]. However, these models are not compatible with
the epidemiologic evidence among HL survivors, for
whom the risk of SC continues to increase with increasing
radiation doses above 30 Gy [5,7,8,18]. A recently devel-
oped mechanistically-based model of radiation carcino-
genicity [19] provides estimates of second lung and breast
cancer risk at high radiation doses (≥ 20 Gy) more com-
patible with epidemiological evidence [5,7,8].
The aims of this study were to quantify the reduction of
radiation dose to normal tissues associated with the tran-
sition from 35 Gy mantle RT to 35 Gy IFRT to 20 Gy IFRT
for patients with mediastinal HL, and to integrate this data
in a radiobiological model to estimate the associated
reductions in risk of radiotherapy-induced breast and
lung cancer.
Methods
Dose distributions were estimated for forty-one consecu-
tive retrospectively identified patients with Stage I-III HL,
who received mediastinal RT from January 2004 to July
2005 at the Princess Margaret Hospital, Canada. Pre-
pubertal patients, those presenting with infradiaphrag-
matic disease only, and those receiving palliative RT, were
excluded. Patient details are summarized in Table 1. All
patients received chemotherapy prior to RT, most com-
monly ABVD (doxorubicin, bleomycin, vinblastine,
dacarbazine). Approval from the research ethics board
was obtained for this study.
Radiotherapy technique
Patients were planned in the supine position, with neck
extended, typically with arms akimbo and the upper torso
immobilized in a Bodyfix® device. For each patient, three
treatment plans were constructed using the patient's plan-
ning CT data set: 35 Gy in 20 fractions mantle RT (historic
treatment), 35 Gy in 20 daily fractions IFRT (current treat-
ment), and 20 Gy in 10 daily fractions IFRT (potential
future practice). Figures 1 and 2 show digitally recon-
structed radiographs demonstrating typical RT field bor-
ders for 35 Gy mantle RT and IFRT, respectively.
For IFRT planning, clinical target volumes (CTV), plan-
ning target volumes (PTV), field borders and shielding
were the same as those used for the actual IFRT delivered.
The CTV typically consisted of the nodal regions involved
with HL at the time of diagnosis, accounting for reduction
in mediastinal width due to chemotherapy. Adjacent
nodal regions were included in accordance with guide-
lines by Yahalom [20], with field borders as follows:
upper border: C5-6 interspace (or at superior edge of lar-
ynx if supraclavicular nodes were involved); lower border:
the lower of 50 mm inferior to the carina or 20 mm below
the pre-chemotherapy inferior extent of disease; laterally:
the post-chemotherapy volume with a 10–15 mm margin
from CTV to shielding edge. Axillary RT was given only to
axillary nodal groups that were involved at the time of
diagnosis. The treatment volumes were identical for the
35 Gy and 20 Gy IFRT plans.Page 2 of 11
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tomic landmarks [20], extending from the mastoid proc-
ess superiorly to the diaphragmatic insertion inferiorly,
encompassing the bilateral axillae and extending laterally
just beyond the humeral heads. Lung shields were placed
10–15 mm from the mediastinal contour and laterally fol-
lowed the inner rib margins. Humeral head shielding
throughout the RT course, as well as anterior laryngeal
and posterior spinal cord shielding introduced at 24.5 Gy
was planned. The cardiac dose was limited to = 30 Gy,
below a transition zone located at 50 mm inferior to the
carina.
For all treatment scenarios, the radiation field arrange-
ment utilized opposed anterior and posterior beams,
ensuring coverage of the CTV within ± 5% of the prescrip-
tion dose, with point maximum doses within the treated
volume no more than 110% of the prescription isodose
accepted. All treatment plans were generated using the
Pinnacle® planning system, version 6.2b (ADAC Laborato-
ries, Milpitas, CA).
Calculating radiation dose to normal tissues
Contouring of the thyroid gland, bilateral female breasts,
bilateral lungs, the whole heart, and the proximal coro-
nary arteries (PCA) was performed under the supervision
of a diagnostic radiologist (NP), and utilizing the cross-
sectional anatomy illustrated in the Visible Human
Project®datasets [21]. Given these organ contours, organ-
specific differential dose volume histograms (DVH) were
calculated using the Pinnacle treatment planning system.
Integral organ doses were calculated by summing the
DVH distributions, and mean doses as the ratio of integral
dose to organ volume.
The percentage reductions in integral dose and mean dose
to different organs associated with the transition from 35
Gy mantle RT to 35 Gy IFRT or 20 Gy IFRT was calculated
for each patient. Differences in mean or integral organ
doses, between the three protocols, were assessed using
the Wilcoxon signed rank test. To quantify the reduction
in the volume of breast and lung tissue exposed to low-
dose radiation, we utilized dose-volume thresholds that
have been previously associated with increased risks of
secondary malignancy in HL patients: bilateral breast V4
(the volume of tissue receiving ≥ 4Gy) [5,8,22,23] and
bilateral lung V5 [22]. V30 for the whole heart was also cal-
culated [23].
Second cancer risk modeling
Given a dose-volume histogram (DVH) for a normal tis-
sue organ, and assuming each part of the organ in ques-
tion is independent in terms of tumor initiation, the
excess relative risk (ERR = Relative Risk (RR) -1) for organ-
specific radiation-induced cancer induction can be esti-
mated, provided that the dose-cancer-risk relation is
known over the relevant dose range for that organ.
Table 1: Description of baseline patient characteristics
Characteristics Number
Gender
Females 25 (61%)
Males 16 (39%)
Median age (range) 27 (14–58 years)
Smokers (current/ex-smoker) 14 (34%)
Pathology
Nodular Sclerosing 39 (95%)
Nodular Lymphocyte Predominant 1 (2%)
Mixed Cellularity 1 (2%)
Stage I 4 (10%)
II 34 (85%)
III 2 (4%)
N/A (Relapse) 1 (2%)
Bulky disease * 28 (72%)
Chemotherapy Regimen
ABVD 38 (93%)
Other 3 (7%)
Median cycles (range) 4 (3–8)
35 Gy IFRT plan – Treatment Indication
Adjuvant 37
Post Transplant 3
Adjuvant Post-Relapse 1
* Bulky disease was defined as ≥ 5 cm on CT scan, and/or a thoracic ratio of maximum transverse mass diameter ≥ 33% of the internal transverse 
thoracic diameter measured at the T5/6 intervertebral disc level on chest radiography.Page 3 of 11
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doses were obtained for breast and for lung, using a cell
initiation/inactivation/proliferation model [19], which
had previously been validated using recent radiation-
induced second-cancer data in Hodgkin's disease patients
treated with extended field RT [19]. This quantitative,
mechanistic model of radiation-induced cancer risks is an
extension of the standard initiation/inactivation cancer
risk model [17]. Specifically the standard model predicts
essentially zero radiation-related cancer risk at high doses,
i.e. comparable to the prescribed tumor dose, due to radi-
ation inactivation (killing) of radiation-initiated, pre-
malignant cells. The more recent cancer-risk model [19],
takes into account post-inactivation cellular repopulation
Digitally reconstructed radiographs demonstrating: mantle RT field (anterior beam shown)Fi ure 1
Digitally reconstructed radiographs demonstrating: mantle RT field (anterior beam shown).Page 4 of 11
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ated radiotherapy [24]. In terms of carcinogenesis, repop-
ulation largely cancels out the effects of cellular
inactivation, primarily because some of the proliferating
cells carry and pass on pre-malignant damage produced
earlier in the treatment. This extended model thus predicts
substantial second-cancer risks even at doses as high as the
prescribed tumor dose, consistent with the recent epide-
miological data [5,7,8].
This cell initiation/inactivation/proliferation model [19]
provides a practical approach to predicting organ-specific
high-dose cancer risks based on a) cancer risk data from
Atomic bomb survivors (who were exposed to lower
Digitally reconstructed radiographs demonstrating: mediastinal involved field RT (IFRT)Fi ure 2
Digitally reconstructed radiographs demonstrating: mediastinal involved field RT (IFRT).Page 5 of 11
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exposure, gender, ethnicity) of the population/individual
of interest, and c) two organ-specific parameters describ-
ing radiation-induced cellular repopulation, which have
previously been estimated both for breast and lung [19].
First, ERRs are directly estimated for single radiation expo-
sures at moderate doses, based on cancer incidence data
among Atomic bomb survivors [25]. Second, a well estab-
lished methodology described by Land and colleagues
[26] (and almost identically in the recent BEIR-VII report
[27] is used to adjust the dose-dependent ERRs from the
Atomic bomb survivors to apply to the demographics
(age, time since exposure, gender, ethnicity) of the indi-
vidual(s) under study. These two steps were implemented
through publicly available on-line software (Interactive
RadioEpidemiological Program, IREP version 5.3) [28].
Finally, these moderate-dose ERR estimates for single
exposures were adjusted to fractionated high-dose radia-
tion exposure, using the initiation/inactivation/prolifera-
tion model [19] outlined above. The key parameter here,
which has already been estimated for breast and lung [19],
describes the ratio, r, of the per-cell proliferation rate for
pre-malignant cells to the per-cell proliferation rate of
normal cells. The values used in the present paper, slightly
modified from those used earlier [19], are r = 1 for lung,
and r = 0.825 for breast (values used earlier were r = 0.96
for lung, and r = 0.76 for breast, the current values give
slightly better agreement with the earlier extended-field
epidemiological data) [5,7]. For details regarding the
modeling, including key assumptions, and mathematical
estimation of ERR see Additional file 1.
Given the organ-specific ERR estimates for any given dose
and fractionation scheme, the DVH data described above
was used to estimate ERRs for radiotherapy-induced
breast and lung cancer. In this "dosimetric + risk-mode-
ling" method, each incremental small volume in the
DVH, ΔVj (j = 1,200), is associated with a total dose Dj =
jΔD. Given the associated ERR (Dj), estimated as
described above, the overall predicted ERR is the volume-
average of these local ERRs, i.e. ERR = (1/V)∑j ERR (Dj)
ΔVj, where V is organ volume. The modeling assumed that
RT was given using fractions of prescribed daily dose =
1.75 Gy-2 Gy, with no treatment on weekends. ERR esti-
mates would not vary significantly with changes in daily
fraction size within a clinically realistic range.
In order to compare with results from the earlier
extended-field radiotherapy, which is largely for prescrip-
tion doses above 30 Gy [5,7,8], three representative
patients were selected for analysis. These patients respec-
tively had values for the mean female breast dose, mean
female lung dose, and mean male lung dose that were
closest to the median values of the whole group when
treated with 35Gy mantle field RT (i.e. their radiation
exposure with traditional RT fields and dose was the most
representative). For each of these representative patients,
ERR estimates were made for each of the three RT scenar-
ios (35 Gy mantle field, 35 Gy IFRT, and 20 Gy IFRT).
Results
Radiation dose reduction
The median values among the 41 treated patients of the
mean organ doses for the three treatment plans are shown
in Table 2. Compared to 35 Gy mantle RT, the median
mean organ doses from 35 Gy IFRT were significantly
reduced (p < 0.001) for all studied organs except thyroid.
Compared to 35 Gy mantle RT, 35 Gy IFRT reduced the
median value of the mean dose to the female breast by
64%, the lung by 24%, the whole heart by 29%, and the
proximal coronary arteries by 2%. The small but statisti-
cally significant reduction in mean dose to the proximal
coronary arteries was largely attributable to 5 cases in
which the CTV was located in the superior mediastinum,
allowing the IFRT plans to reduce the mean dose to the
PCA. The reductions in breast V4, lung V5 and cardiac V30
were 68%, 37% and 29% respectively.
As expected, reducing the IFRT prescription dose from 35
Gy to 20 Gy reduces all the mean organ doses by the same
proportion, approximately 43%. Thus, compared with 35
Gy mantle, 20 Gy IFRT reduces the median value of the
mean dose to the female breast by 80%, the lung by 56%,
the whole heart by 59%, the proximal coronary arteries by
44%, and the thyroid by 43%. Reducing the prescribed
IFRT dose from 35 Gy to 20 Gy produced a greater
decrease in the mean dose to the PCA and the thyroid,
than the change from mantle RT to IFRT. Breast V4 and
lung V5 were reduced by 72% and 45% respectively. Figure
3 demonstrates the proportional reduction in integral
dose to normal tissues for these three treatment scenarios.
Second cancer risk reduction
Following RT for HL, breast and lung cancer account for
the greatest burden of excess risk [1]. The estimated ERRs
for radiation-induced breast cancer and lung cancer in
never-smokers are shown in Table 3. The estimated age-
specific ERRs at a time 20 years is shown after RT, but the
relative reduction in ERRs (e.g. 35 Gy mantle vs. 35 Gy
IFRT) would be unchanged for any other time post RT.
Younger patients were predicted to have higher ERRs for
SC than older patients, but similar proportional reduc-
tions in the ERR.
Thus, for example, moving from 35 Gy mantle RT to 35
Gy IFRT is predicted to reduce the ERR for female breast
and lung cancer by approximately 65%, and the ERR for
male lung cancer by approximately 35%. Moving from 35
Gy IFRT to 20 Gy IFRT is predicted to reduce ERRs by a fur-
ther 36% to 43%.Page 6 of 11
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Different parts of each relevant organ are subject to a
range of doses, from the prescription dose (or slightly
higher) down to low doses. Figure 4 shows the estimated
contribution of different doses deposited within a given
organ to the estimated ERRs, for two representative cases.
The curves are normalized so that the area under each
curve is the relevant ERR in Table 3. Both low doses and
high doses contributed significantly to the predicted ERR.
For the lung, the largest predicted contributions to the
total ERR, per unit dose, came from high doses (i.e. close
to the prescribed dose), with a small secondary maximum
at quite low doses. For the breast, a broader distribution
was seen, with the largest predicted contributions per unit
dose occurring at total doses of 1–3 Gy, but with signifi-
cant contributions from a broad range of doses, including
a secondary peak at higher doses, near the prescription
dose.
Discussion
Hodgkin lymphoma survivors are known to be at
increased risk of radiation-induced SC [1,5,7,29] and car-
Proportional reduction in integral dose to normal tissuesFigure 3
Proportional reduction in integral dose to normal tissues
Table 2: Mean radiation dose to normal tissues
Thyroid (Gy) Breast (Gy) Lung (Gy) Heart (Gy) PCA* (Gy)
35 Gy Mantle (q1-q3) 34.4 (34.1–34.8) 9.0 (7.7–11.5) 14.7 (14.1–15.7) 24.2 (22.6–26.3) 34.7 (34.1–35.2)
35 Gy IFRT (q1-q3) 34.6 † (33.5–35.3) 3.2 (1.8–4.4) 11.2 (9.7–12.9) 17.2 (8.7–22.0) 33.9 (29.4–34.9)
20 Gy IFRT (q1-q3) 19.7 (19.2–20.2) 1.8 (1.0–2.6) 6.4 (5.5–7.3) 9.9 (5.0–13.2) 19.6 (17.2–20.0)
all figures quoted are median values, with first and third quartiles (q1-q3)
* PCA = proximal coronary arteries
† Compared to 35 Gy mantle RT, mean doses were significantly reduced (p < 0.001) for all organs with 35 Gy IFRT and 20 Gy IFRT, except for the 
mean dose to thyroid, which was not significantly reduced with 35 Gy IFRT.Page 7 of 11
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estimates are primarily derived from HL survivors treated
more than 20 years ago with mantle, extended mantle or
subtotal nodal RT [1,6,29,32] whereas contemporary RT
protocols utilize involved-field (IFRT) given following
chemotherapy. To our knowledge, this is the first study to
quantify both the reduction in radiation dose to normal
tissues delivered with past, current and potential future
treatment, and to model the associated reduction in sec-
ondary breast and lung cancer risk.
While the motivation for IFRT usage is largely to reduce
late effects, in particular SC and cardiac sequelae, quanti-
fying such risk reductions through epidemiological stud-
ies is challenging. In particular, the cancer-registry
information that proved pivotal in quantifying SC risks
after HL [5,7,8] does not generally contain detailed indi-
vidual-level data on treatment. In contrast, clinical trial
datasets contain detailed information regarding initial
treatment and may potentially facilitate detailed analyses
of the association between specific treatments and SC risk.
As noted above, a recent meta-analysis of 10 trials com-
paring IFRT to EFRT [13] demonstrated no significant dif-
ference in SC risk (OR = 1.17 favoring IFRT; p = 0.28),
with a similar finding reported in a single BNLI study [14].
A major limitation of clinical trial data, however, is that
the specifics of salvage therapy are often not recorded, and
the completeness of long-term follow-up and SC report-
ing may be limited, potentially allowing for misclassifica-
tion of exposures or outcome. In addition, observational
studies cannot predict the potential reduction in SC risk
associated with the reduction in IFRT dose to 20 Gy,
which may emerge as standard treatment for adult HL
[11,12].
We have used a dosimetric risk-modeling approach to sec-
ond-cancer risk estimation: compared to mantle RT, we
have measured the reduction in dose to relevant normal
tissues associated with modern IFRT, and then modeled
the associated reductions in ERR for radiation-induced
breast and lung cancer. The merit of the approach taken
here is that it employs both observations from cohort and
case-control studies, as well as biological evidence, to pre-
dict SC risk based on radiation exposures, without having
to wait for decades to observe the actual risk. It is notable
that radiation carcinogenicity has historically been mod-
eled primarily as a balance between cellular initiation of
malignancy and cellular killing, in which the cancer
induction decreases with increasing doses due to greater
cell killing [33,34]. In many cases, however, these models
predict a reduction in SC risk with RT doses greater than
5–10 Gy, which is clearly contrary to the results of large
studies of HL survivors demonstrating increasing risks
with escalating doses beyond 20 Gy [5-8,19]. For women
diagnosed in their 20's, reported RRs of breast cancer have
typically been 3–10 [1,29,35], although higher RRs have
been reported in other studies of young women receiving
RT [1,6]. Relative risks among women treated in their 30's
have been lower, generally consistent with the risk found
in this study after 35 Gy mantle RT [1,29]. Similarly,
reported RRs of lung cancer typically range from 4–12,
with higher RR amongst those treated at younger ages
[1,6]. The risks estimated in the 35 Gy mantle scenario in
this study are generally in keeping with these published
values, providing some external validation of the mode-
ling. In addition, modeled estimates predicted decreasing
ERRs of breast and lung cancer with older age at HL treat-
ment, are consistent with the results of several large cohort
studies of HL survivors [1,5,7,18,22].
Breast cancer is the most common second malignancy
among female HL survivors, particularly those treated at
young ages [32]. The reduction in radiation dose and SC
risk associated with the transition to IFRT was most evi-
dent for the female breast, where the estimated ERR for
radiation-induced breast cancer decreased by 64%. This is
largely attributable to the smaller volume of breast tissue
irradiated when axillary fields are omitted.
Lung cancer remains the most common cause of death
from SC following HL [1,8,29]. The transition from man-
tle to 35 Gy IFRT was associated with a 67% and 36%
Table 3: Estimated excess relative risk (ERR*) of secondary breast and lung cancer 20 years after radiation exposure
Female Breast Female Lung Male Lung
Age at RT (yrs) Age at RT (yrs) Age at RT (yrs)
20 30 20 30 20 30
35 Gy mantle RT (95% CI †) 4.6 (2.5–13.3) 2.1 (1.07–6.1) 18.4 (7.0–56.3) 7.6 (3.0–21.8) 12.6 (5.3–26.4) 5.2 (2.3–10.1)
35 Gy IFRT (95% CI) 1.7 (0.90–4.7) 0.74 (0.38–2.2) 6.1 (2.3–18.8) 2.5 (0.99–7.3) 8.3 (3.5–17.3) 3.4 (1.5–6.6)
20 Gy IFRT (95% CI) 1.06 (0.58–3.0) 0.47 (0.24–1.4) 3.5 (1.3–10.7) 1.4 (0.57–4.1) 4.7 (2.0–9.9) 1.9 (0.86–3.8)
* Excess Relative Risk (ERR) = Relative Risk (RR)-1
† 95% CI = 95% confidence interval
The ERR calculations were performed on three representative patients who had values for the mean female breast dose, mean female lung dose, 
and mean male lung dose that were closest to the median values of the whole group when treated with 35 Gy mantle field RT.Page 8 of 11
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female and male case, respectively. These decreases are
largely attributable to the reduction in lung dose with the
omission of axillary fields, as well as the more superior
placement of the inferior border in IFRT.
The results here suggest that using low-dose IFRT (20 Gy),
as opposed to the standard 35 Gy IFRT, would be expected
to be associated with further second-cancer risk reduction,
with point estimates of the reduction in excess relative
risk, in the range from 36–43%. This observation provides
a significant support for the rationale behind low-dose
IFRT trials currently ongoing [11,12].
Mediastinal RT is also associated with cardiotoxicity
[2,31,23]. Hancock et al [23] found that HL patients
Estimated contribution of different doses within female breast and male lung tissue to the excess relative risk of secondary can-cerFigure 4
Estimated contribution of different doses within female breast and male lung tissue to the excess relative risk of secondary can-
cer.Page 9 of 11
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higher risk of cardiac death than those receiving lower
doses. For the majority of patients in this study, the tran-
sition to IFRT decreased the mean dose to the whole heart
significantly but did not reduce the mean dose to the PCA
below 30 Gy. This suggests a possible reduction in the
incidence of valvular or conduction defects associated
with the transition to IFRT. For most patients however,
since mean dose to the heart was not decreased, major
reductions in the risk of ischemic heart disease will either
depend on future dose reductions, or additional volume
reductions beyond current IFRT techniques.
This study has limitations that warrant consideration.
Firstly, the biologic model applied [19] has inherent lim-
itations, and is based on four assumptions [see Additional
file 1]. These assumptions include those regarding esti-
mating risks for mradiat, the number of pre-malignant stem
cells, dose per fractionation independence, interfraction
and post-radiation cellular proliferation. For a more com-
plete explanation see Additional file 1. In addition, there
was inter-physician variability in contouring of target vol-
umes and shielding placement for the IFRT plans that may
influence the measured dose to normal structures,
although its overall effect in this study likely reflects (or
underestimates) the heterogeneity that exists in modern
clinical practice [36]. In this current study, whole body
organ doses were not calculated, and so it was not possi-
ble to estimate the reduction in whole body cancer risk.
Instead we chose to focus on breast and lung, as these are
the two anatomic sites that dominate when considering
radiation-induced SC in HL survivors. In addition, ERR
estimates were based on only three cases, and although
these cases were selected to be representative of the mean
dose delivered to breast and lung with 35 Gy mantle RT,
the broad distribution of ERR reductions that might be
expected in a large population of patients has probably
been under-sampled. Finally, we recognize that SC risks
involve complex interactions of host, environmental and
non-radiation treatment factors. And so while the SC risk
estimates presented here consider radiation dose, normal
tissue volume, patient age, gender and smoking status,
they nevertheless over-simplify these complex interac-
tions [37].
Our results demonstrate that the transition from mantle
RT to IFRT and reduced-dose IFRT is associated with sig-
nificant reductions in radiation dose to normal tissues.
Further, modeling results predict that these reductions in
radiation exposure will be associated with significant
reductions in the risks of breast and lung cancer following
IFRT for HL. Ultimately, extended follow-up on patients
treated with modern IFRT will be required to definitively
quantify the reduction in SC risk associated with this
approach.
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